Sponsored by
We are proud to announce we have awarded a $100,000 venture philanthropy grant to Autem Therapeutics to support research on AutEMsys™, a non-invasive, low-intensity radiofrequency electromagnetic field (RF-EMF) device, being studied as a potential new treatment approach for glioblastoma. The grant will support study of RF-EMF exposure in patient-derived "tumoroids" - three-dimensional models grown directly from patient tumor tissue - and early clinical research in newly diagnosed glioblastoma patients. This research will explore whether RF-EMF exposure can shift the electrical balance of tumor-infiltrated brain tissue toward a state that suppresses tumor growth, further inform its mode of action and generate early data on patient experience and outcomes.